Page last updated: 2024-12-06

a 78773

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

A 78773: a 5-lipoxygenase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71460
CHEMBL ID59598
SCHEMBL ID1807930
MeSH IDM0220367

Synonyms (23)

Synonym
(r)-(+)-n-{3-[5-(4-fluorophenoxy)furan-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea
n-{3-[5-(4-fluorophenoxy)furan-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea
(s)-(-)-n-{3-[5-(4-fluorophenoxy)furan-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea
n-{3-[5-(4-fluorophenoxy)-2-furyl]-1-methylprop-2-ynyl}-n-hydroxyurea(a-78773)
bdbm50029775
n-{3-[5-(4-fluorophenoxy)-2-furyl]-1-methylprop-2-ynyl}-n-hydroxyurea
OPREA1_560784
urea, n-(3-(5-(4-fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-n-hydroxy-
n-(3-(5-(4-fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-n-hydroxyurea
a-78773
n-hydroxy-n-(4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-yl)urea
a 78773
AKOS000280128
141579-67-1
CHEMBL59598 ,
1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea
ccris 8531
SCHEMBL1807930
n-{4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl}-n-hydroxycarbamimidic acid
DTXSID90931132
n-hydroxy-n-(4-(5-(4-fluorophenoxy)2-2furyl)-3-butyn-2-yl)urea
urea, n-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propyn-1-yl]-n-hydroxy-
AKOS040747676
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)0.29800.00462.018210.0000AID6787
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID181942Percent inhibition of LTE4 formation in rats from peritoneal fluids at a dose of 200 micro mol/Kg1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID92719Compound was evaluated for inhibiting production of LTB4 in calcium Ionophore (A23187) activated human whole blood.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.
AID92880Inhibition of 5-lipoxygenase (5-LO) measured as LTB4 production in human whole blood stimulated with calcium ionophore (A23187).1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID180525The compound was tested for in vivo activity for rat anaphylaxis leukotriene formation on an oral dose of 30 micro mol/Kg1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID177815Compound was evaluated in vivo for the rat anaphylaxis leukotriene formation at an oral dose of 30 umol/kg1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID126490Rate of glucuronidation was determined using a microsomal preparation from the monkey liver tissue1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID69705-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID18863Rate of glucuronidation (nmol/min/mg protein) in monkey microsomes1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID24073t1/2 in monkey after PO dose (2 umol/kg)1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID6787Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (86.67)18.2507
2000's2 (13.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.23 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.88%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]